Could an OCD drug ease long COVID brain fog and fatigue?
NCT ID NCT05874037
First seen Jan 07, 2026 · Last updated May 09, 2026 · Updated 17 times
Summary
This study tested whether fluvoxamine, an FDA-approved OCD medication, can improve long COVID symptoms like trouble concentrating, anxiety, depression, and fatigue. Researchers enrolled 191 adults in Missouri and Illinois who had COVID at least 3 months earlier. Participants took fluvoxamine or a placebo and rated their symptoms daily to see if the drug helped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.